Epirium Bio

Executive Summary

Epirium Bio is a clinical-stage biopharmaceutical company pioneering orally bioavailable small molecules that modulate PGE-2 signaling to restore tissue homeostasis. Its lead candidate, MF-300, is currently in a Phase 2b study for sarcopenia, a condition characterized by age-related muscle loss. The company's platform aims to resolve inflammation, stimulate regeneration, and reduce fibrosis, with additional preclinical programs in neuromuscular, inflammatory, and fibrotic diseases. Based in San Diego, Epirium is privately held and has not disclosed its total funding or valuation. The Phase 2b data for MF-300 is a key near-term value driver, as positive results could position the company for late-stage development and potential partnership interest in the growing sarcopenia market. While still early, the platform's broad applicability across multiple disease areas adds strategic flexibility.

Upcoming Catalysts (preview)

• Q3 2026Phase 2b top-line data readout for MF-300 in sarcopenia55% success
• Q4 2026Initiation of a Phase 1/2 study in a second indication (e.g., fibrotic or inflammatory disease)40% success
• TBDPotential partnership or licensing deal for MF-300 or platform technology30% success